Keya Medical’s anchor product DEEPVESSEL FFR, an AI-based noninvasive CT-FFR product, is the first AI product approved for marketing by NMPA, conquering an enormous market for clinical use.
DeepVessel is the first license AI medical imaging for coronary artery assessment. Image credit: DeepVessel
The Shenzhen-based Keya Medical, which provides the first and only NMPA-approved noninvasive CT-FFR, recently closed a Series B+ fundraising at am amount of CNY 150 million. GGV led the investment, with participation from by Kunlun Internet Intelligent Industrial Investment Fund, Shanghai Guofang FOF and Alwin Capital.
Keya Medical is the first and only artificial intelligence (AI) medical company granted a Type III medical device registration certificate approved by the National Medical Products Administration (NMPA).
Its anchor product, DEEPVESSEL FFR, is the world’s first licensed noninvasive CT-FFR product based on deep neural networks. Including DEEPVESSL’s two products ANGIO and CARS. The three products form a systematic AI medical imaging for coronary arteries.
The most valuable Chinese company in the medical imaging segment – Mindray Medical (300760:SZ) – was trading at CNY 213 as of 11:36 AM, August 13, 2020, at a market value of CNY 384.77 billion.